Innovation in immunomodulation

ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is  developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.

Latest news

HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial
Science & Medicine  Leadership & Corporate 
Read more
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
Science & Medicine 
Read more
ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer
Leadership & Corporate 
Read more

Upcoming events

Antibody Engineering & Therapeutics Europe | Virtual format

From  Aug 25, 2020  to  Aug 27, 2020 

Read more

PEGS Summit 2020

From  Aug 31, 2020  to  Sep 04, 2020 

Read more

ESMO 2020

From  Sep 18, 2020  to  Sep 22, 2020 

Read more


Subscribe to receive our press releases and news